This mixed-methods feasibility study explored whether cranial electrotherapy stimulation (CES) delivered via the Alpha-Stim AID device could be acceptable and tolerable as a potential treatment for anxiety associated with breathlessness in people with advanced chronic respiratory disease receiving hospice care. The study aimed to assess deliverability within hospice services and gather feasibility data to inform a future fully powered randomized trial.
The investigation was a multicentre, non-randomised interventional feasibility study with a parallel usual-care control group. Intervention participants used Alpha-Stim AID for eight weeks, followed by a four-week follow-up period. The report emphasises that this feasibility study was not powered to assess clinical efficacy.
Participants were adults with chronic respiratory disease referred to hospice services who had clinically significant symptoms of anxiety and breathlessness as assessed by the Integrated Palliative Outcome Scale. At the primary recruitment site, 12.5% of screened patients met eligibility criteria. In total, 29 unique participants were recruited to the study.
Intervention arms received the Alpha-Stim AID device for use over an eight-week period. Two dosing strategies were used: a fixed dose and a personalised dose. The study focused on the practical aspects of delivering CES in the hospice environment and assessing participant acceptability rather than determining comparative efficacy between dose strategies. Details of specific dosing parameters were not reported in the summary.
Outcome assessment combined quantitative repeated measures and other feasibility metrics. Daily numerical rating scales captured day-to-day fluctuations in anxiety and breathlessness. Standardised questionnaires, including the Generalized Anxiety Disorder-7 (GAD-7), were used to assess anxiety over time. The study tracked adverse events, withdrawals, and outcome measure completion to evaluate tolerability and feasibility.
Three participants (10.3% of those enrolled) withdrew from the study; none of these withdrawals were attributed to CES. Most reported adverse events were mild. Headache was a frequently reported symptom and occurred across both control and intervention groups. Overall, the device was described as generally tolerable by participants who enrolled.
Feasibility metrics were favourable: outcome measure completion rates were high, and overall missing data were low, with data missingness below 6.4%. The investigators concluded the Alpha-Stim AID intervention was deliverable within hospice services and acceptable to the majority of participants who enrolled.
Daily numerical rating scales for anxiety and breathlessness showed fluctuation day to day and remained broadly static across the observation period. In contrast, scores on the GAD-7 improved over time across all groups, including control. The authors reiterate that this feasibility study was not powered to determine clinical efficacy, so observed changes cannot be interpreted as evidence of a treatment effect.
The study concludes that CES using Alpha-Stim AID can be delivered in hospice settings and is generally acceptable and tolerable among participants who choose to enrol. Given the feasibility findings, the authors recommend further evaluation with a fully powered randomized controlled trial including a sham control device to determine whether CES yields clinically meaningful improvements in anxiety for people with breathlessness in palliative care.
Ethical approval was provided by the Brighton and Sussex NHS Research and Ethics Committee (reference 23/LO/0276). The clinical trial registration number is NCT06066658. The authors stated that data generated in the study are available from the corresponding author on reasonable request, subject to appropriate institutional data protection approvals. Declared funders included NIHR, the Wellcome Trust, and the Stoneygate Trust. The authors reported no competing interests.
The primary limitation explicitly acknowledged in the source is that this feasibility study was not powered to evaluate clinical efficacy. Specific dosing parameters and detailed results beyond the summary measures reported were not provided in the source abstract and full details would need to be consulted in the full manuscript or supplementary materials.
For clinicians and researchers in hospice and respiratory care, the key implication is that CES with Alpha-Stim AID is feasible to deliver in hospice settings and merits a definitive randomized trial versus a sham control to establish whether it offers a meaningful clinical benefit for anxiety in patients with breathlessness.